by AARS Blog | Sep 10, 2024 | Blog
Citing “multiple concerns among dermatologists comprising the leadership of the American Acne and Rosacea Society (AARS),” the Society Board of Directors submitted a letter to the editor of the Journal of the Academy of Dermatology that was published today. Among...
by AARS Blog | Aug 28, 2024 | Blog
Oxy Acne Care Gets a Reboot. In honor of its 50th anniversary, the Oxy® Acne Care brand is relaunching with a fresh look. In addition to unveiling a modernized new package design, the brand is introducing two new products: the Oxy Acne Care Body Wash and Sensitive...
by AARS Blog | Aug 14, 2024 | Blog
Izokibep, a novel IL-17A inhibitor, demonstrated statistically significant responses across multiple efficacy endpoints in phase 3 trials for HS at 12 weeks. One-third of patients receiving izokibep 160mg weekly (QW) achieving HiSCR75, compared to 21% receiving placebo...
by AARS Blog | Aug 13, 2024 | Blog
Crown Laboratories, Inc. will acquire all outstanding shares of Revance Therapeutics, Inc. common stock in a merger agreement just announced. Upon completion of the transaction, Crown Laboratories, which owns the PanOxyl line of acne care products, says it expects to...
by AARS Blog | Jul 30, 2024 | Blog
Research posters presented at the Society for Pediatric Dermatology Annual Meeting this month and reported by The American Journal of Managed Care® (AJMC®) show that hidradenitis suppurativa is a cause of psychosocial distress in affected children. One poster by...
